Innovation
Long-term Commitment
True innovation takes time.
Meaningful partnerships require trust.
Great platforms create value over the long term.
We believe continuous commitment, open collaboration, and shared growth are essential to advancing the future of healthcare.
Drug Pipeline
Drug pipelines are the core value assets of biomedical enterprises, covering early candidate compounds, preclinical research varieties, new drugs under development at various stages and iterative improved new drug sequences, covering popular medical segmented tracks such as oncology, autoimmune diseases, anti-infection, neurological diseases and rare diseases.
Targeting medical B2B investment, financing, M&A and industrial cooperation scenarios, we provide all parties in the industrial chain with drug pipeline sorting, value judgment, pipeline valuation, industrial empowerment and transaction docking services. We accurately verify the R&D progress, target innovation, clinical differentiation advantages, patent protection cycle, competitor pattern and commercial potential of pipeline varieties, helping investors screen high-value R&D assets, assisting pharmaceutical enterprises in activating idle pipelines, completing pipeline expansion and industrial integration, and promoting the efficient circulation and industrial implementation of innovative drug assets.
Approved Drugs
Approved drugs are mature pharmaceutical assets with stable commercial capabilities, including approved innovative drugs, generic drugs, modified new drugs and various preparation products, with complete drug approvals, production qualifications, marketing licenses and market circulation permissions. Focusing on the needs of medical B2B industrial transactions and capital operation, the platform provides services such as approved drug asset valuation, variety transfer, profit sharing, market expansion, channel M&A and stock asset activation. We comprehensively verify the marketing compliance, approval validity, quality standards, market sales data, medical insurance access, centralized bidding qualifications and life cycle value of drugs, providing authentic and reliable asset judgment basis for drug variety transactions, enterprise M&A and restructuring, and industrial capital investment, helping pharmaceutical enterprises optimize product matrices, quickly occupy market shares and realize the appreciation of stock assets.
Clinical Trials
Clinical trials are the core key link for new drugs from R&D to marketing, including Phase I, II, III clinical trials and post-marketing Phase IV clinical studies. They serve as the core basis for verifying the safety, effectiveness and tolerability of drugs, as well as a key indicator for medical investment project value judgment.
Full-cycle Clinical Progress Verification
Covering the full life cycle of new drug R&D including preclinical, Phase I, II, III and post-marketing Phase IV, we carry out systematic clinical progress verification and node management for various medical innovative projects such as oncology drugs, rare disease drugs, innovative preparations and biotech drugs.
Clinical Data Authenticity & Effectiveness Evaluation
Focusing on the core value of clinical trials, we conduct all-round verification and professional evaluation of original clinical trial data, subject data, efficacy endpoint data and safety data. We strictly verify the traceability, completeness, consistency and compliance of data, and identify common problems such as data fraud, data missing, data deviation and test errors.
Clinical Compliance & Risk Assessment
In accordance with domestic NMPA and GCP specifications and international clinical supervision standards, we conduct special review on the full-process compliance of clinical trials, covering core links such as trial protocol compliance, ethical filing and approval, clinical institution qualifications, researcher qualifications, trial process management, sample management and adverse reaction reporting.
Biotech Companies
Biotech companies are the core entities of the biomedical innovation industry, focusing on cutting-edge fields such as target research and development, biotechnology transformation, innovative drug development and biological preparation R&D, featuring high R&D investment, high technical barriers, high growth potential and long return cycles. Facing the medical B2B capital market, the platform provides integrated capital services for innovative biotech enterprises including accurate investment and financing docking, equity M&A, strategic cooperation, industrial empowerment and listing cultivation.
Technology Platforms
Pharmaceutical technology platforms are the underlying core infrastructure supporting the continuous innovation and iterative R&D of biomedicine, covering drug discovery platforms, target verification platforms, ADC drug technology platforms, cell and gene therapy platforms, protein engineering platforms, synthetic biology platforms and CMO/CDMO industrialization technology platforms.